Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601635 · ClinicalTrials.gov registry record · NA
ButyraGen™, Short Chain Fatty Acids and Gut Microbiome
A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT05601635: Completed NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT05601635 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 29 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05601635, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is being conducted to demonstrate short chain fatty acid (SCFA), specifically butyrate, generation in stool, blood and urine in response to oral intake of ButyraGen™.
Primary Outcome
Outcome measure will be quantified via GC-FID
Interventions
- DIETARY_SUPPLEMENT ButyraGen™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2023-01-11 |
| Phase | NA |
What the finished NCT05601635 record still lists
NCT05601635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which ButyraGen™ is the first listed.
NCT05601635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05601635 about?
NCT05601635 is a clinical study titled "ButyraGen™, Short Chain Fatty Acids and Gut Microbiome". This study is being conducted to demonstrate short chain fatty acid (SCFA), specifically butyrate, generation in stool, blood and urine in response to oral intake of ButyraGen™.
What is the current status of trial NCT05601635?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2022-10-19. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT05601635?
The interventions under investigation include: ButyraGen™ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05601635?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05601635's enrollment target sits among peer trials
29 1702nd of 2000 higher than 297 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI